Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | NCF1 | P14598 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15314555 | 1.00 | ALDH1A1 (0.34) | ALDH1A1L3MBTL1NCF1SMN1; SMN2MAPK1 | |
| SCHEMBL22306166 | 0.79 | ATM (0.34) | ALDH1A1L3MBTL1NCF1SMN1; SMN2MAPK1 | |
| SCHEMBL22306162 | 0.79 | ATM (0.34) | ALDH1A1L3MBTL1NCF1SMN1; SMN2MAPK1 | |
| SCHEMBL8966743 | 0.79 | ATM (0.34) | ALDH1A1L3MBTL1NCF1SMN1; SMN2MAPK1 | |
| SCHEMBL18612603 | 0.76 | ALDH1A1 (0.33) | ALDH1A1L3MBTL1 | |
| SCHEMBL20193412 | 0.76 | ALDH1A1 (0.33) | ALDH1A1L3MBTL1NCF1 | |
| SCHEMBL24811602 | 0.76 | — | — | |
| SCHEMBL22995860 | 0.73 | — | — | |
| SCHEMBL19199012 | 0.73 | — | — | |
| SCHEMBL18068174 | 0.73 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11912723-B2 | KRAS modulators and uses thereof | QUANTA THERAPEUTICS, INC. (US) | 2024-02-27 | — | — | US | disclosed |
| US-20230374042-A1 | KRAS MODULATORS AND USES THEREOF | QUANTA THERAPEUTICS, INC. | 2023-11-23 | — | — | US | disclosed |
| WO-2022256459-A1 | KRAS MODULATORS AND USES THEREOF | QUANTA THERAPEUTICS, INC. (US) | 2022-12-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230374042-A1 | KRAS MODULATORS AND USES THEREOF | KRAS, NRAS, HRAS | ALDH1A1 3733/4885L3MBTL1 3099/4885NCF1 1608/4885 |
| US-11912723-B2 | KRAS modulators and uses thereof | KRAS, NRAS, HRAS | ALDH1A1 3733/4885L3MBTL1 3099/4885NCF1 1608/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.